Advisers to the U.S. Food and Drug Administration voted unanimously Thursday to recommend a monoclonal antibody developed by Sanofi (SAN.FR) and AstraZeneca (AZN.LN) to protect infants from respiratory syncytial virus. RSV is a common respiratory virus that can cause severe illness in infants and older adults. In a separate vote, 19 of 21 members voted to recommend the monoclonal antibody, nirsevimab, for prevention of RSV lower respiratory disease in children up to two years of age who remain vulnerable to severe RSV. FDA advisory-committee votes are not binding, but the agency often follows committee recommendations. Shares of Sanofi and AstraZeneca were both up 1.3% on Thursday.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
Any recommendation, opinion or advice regarding securities or markets contained in such material does not reflect the views of TD Ameritrade, and TD Ameritrade does not verify any information included in such material.